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Tackling long-standing problems in science or refuting dogma is not necessarily the best strategy 
for a young investigator seeking tenure. But just like investing in risky stocks when young, perhaps 
it should be. Amy Maxmen reports.Larry Page, cofounder and president 
of Google, and Steven Jobs, cofounder 
and CEO of Apple, give a lot of lip-ser-
vice to thinking “outside the box” and 
overcoming the fear of failure. After all, 
this is how they found success. In Jobs’ 
commencement address to Stanford 
University students in 2005, he advised 
graduates, “Don’t be trapped by dogma, 
which is living with the results of other 
people’s thinking.” Similarly, J. Craig 
Venter, the maverick genome sequencer, 
says: “My view is that if it’s the dogma 
of the day, there’s a good chance that 
it’s wrong.” However, many investiga-
tors seeking tenure avoid controversial 
or overly ambitious, long-term projects 
when universities judge them based on 
how reliably their research yields grants 
and publications.
“I think that doing safe projects must 
be ingrained in the philosophy of how 
we train students based on what gets 
rewarded and doesn’t,” says Venter, 
who frequently had his grants turned 
down by the National Institutes of Health 
(NIH). Now, some successful research-
ers who overcame resistance from their 
colleagues and their superiors are look-
ing for ways to make it easier for the next 
generation of creative risk-takers to pur-
sue their scientific ideas within the sys-
tem. Funding agencies are paying atten-
tion too. With a boost from the stimulus 
package, the NIH and the National Sci-
ence Foundation (NSF) have been able to 
set aside more money for unconventional 
research proposals. On September 24th, 
the NIH announced the winners of the 
first Transformative R01 (TR01) grants, 
which are evaluated differently from tra-
ditional R01 grants in order to give ideas 
that may even seem far-fetched a chance 
to completely transform their field. Finally, 
interdisciplinary meetings geared toward 
fostering creative scientific discussions 
are cropping up, and some come with 
prizes to support winning concepts.Beating the Odds
MIT neuroscientist Susumu Tonegawa 
was fired while conducting the research 
that would win him the 1987 Nobel Prize 
for Physiology or Medicine. In his own 
words: “I knew I could do something that 
could be big, so I completely ignored 
everything around me, including my own 
termination.”
Tonegawa had accepted a job offer 
from the Basel Institute for Immunology 
in Switzerland, after his US visa expired. 
Although he did not consider himself an 
immunologist, he wanted to stay active 
in research while waiting until his US visa 
could be renewed. Becoming immersed 
in the field of immunology, he saw the 
enigma of antibody diversity with fresh 
eyes, and he decided it was a problem 
he could attack. “After three years, I was 
told that my appointment was terminated 
because I didn’t have significant publica-
tions. But I ignored that letter and I kept 
working in the lab,” Tonegawa says. He 
returned to the bench day after day and 
eventually convinced the director of the 
Basel Institute to allow him to stay. Five 
years after his arrival, in 1976, Tonegawa 
published the study that would earn him 
the Nobel.
“I keep telling young people, if you 
want to accomplish anything you have 
to be an optimist,” Tonegawa says. “You 
have to control your own life. You have to 
ask yourself why you do science. To put it 
bluntly, publishing papers in prestigious 
journals should not be the goal of a sci-
entist. The goal is to discover something, 
to do something important,” he says.
Tonegawa’s former post-doc, Alcino 
Silva, a neuroscientist at the University 
of California, Los Angeles, came to Tone-
gawa’s immunology lab at MIT wanting 
to delve into neuroscience. His plan was 
to delete genes expressed in the mouse 
hippocampus in order to elucidate the 
genetic basis for learning and memory. 
“People were laughing at us,” says Silva. Cell 1“They said what are these simple-minded 
molecular biologists trying to do?” Nos-
talgically, he adds, “But that was fantastic 
for me because I’m most comfortable as 
an outsider. I grew up in Portugal during 
the revolution, when people stayed up all 
night arguing about the future of the coun-
try. So, to me, arguing is like playing tennis. 
In the beginning there were holes every-
where, but it was so much fun...I wanted to 
change neuroscience and it simply never 
occurred to me that I would fail.”
Tonegawa backed Silva’s prediction. 
“Susumu could have told me, listen, you 
have a nice idea but why not start with 
a solvable problem in immunology, get a 
Nature or Cell paper, and use that paper 
to get a job,” reflects Silva. “Well, had I 
done that, I’d be nowhere. I’d be in some 
minor lab and damned to obscurity for 
the rest of my life.”
After decades of providing a place for 
his students to pursue their ideas with-
out pressure to publish quickly, Tone-
gawa wants to put his philosophy into 
practice on an institutional level. “A strict 
limit on the number of years it takes to 
integrate an assistant professor is too 
strict. There should be flexibility because 
sometimes important work takes a long 
time,” he says. As the new director of the 
RIKEN Brain Science Institute in Japan, 
Tonegawa is installing a flexible tenure 
review system in which investigators can 
chose the timing of their tenure review, 
such that it will start anywhere after 4 to 
6 years of research.
Breaking down Barriers
The difficulty in Tonegawa’s approach lies 
in evaluating the potential of researchers 
without simply counting grant awards 
and publications. Tonegawa would like to 
see more weight placed on the creativ-
ity of an investigator’s research, which 
he assesses by instinct and confirms by 
asking how his experienced and trusted 
colleagues feel.39, October 2, 2009 ©2009 Elsevier Inc. 13
Nobel laureate David Baltimore, a for-
mer president of Rockefeller University, 
the California Institute of Technology, 
and the American Association for the 
Advancement of Science, is known for 
his nose for talent. Over the past four 
decades, Baltimore has trained over 
200 students and post-docs, most of 
whom have gone on to run their own 
labs. Baltimore’s advice on how to 
evaluate potential? “There are no per-
fect measures—in fact, most measures 
are useless. It comes down to talking 
with someone, listening to how they 
respond to questions, seeing whether 
they respond with a sense of the big-
ger picture or if they focus on methods, 
whether they think broadly outside of 
their own particular field or whether they 
narrowly focus their thinking in their own 
area of expertise.”
If department heads and deans con-
sidered qualitative traits such as cre-
ativity, curiosity, and drive to be as 
important as obtaining grants and pub-
lications, payoffs could be higher in the 
long run. At least this is the concept 
behind institutions like the Max Planck 
in Germany and HHMI’s Janelia Farm in 
Virginia. Resources are provided and the 
race for tenure does not exist because 
there is no tenure. Group leaders can 
remain at Janelia Farm indefinitely, as 
long as they pass a review every 5 years 
that assesses qualities like their original-
ity, their creativity, how well they tackle 
important problems, and how well they 
work with others. As director of Jane-
lia Farm, geneticist Gerry Rubin urges 
researchers to pursue projects that 
are long-term, ambitious, or otherwise 
unlikely to be supported by the NIH.
“I think there are types of scientists 
who aren’t being supported in the cur-
rent system and we want to provide a 
home for them,” Rubin says. “I tell them 
that they need to believe in themselves 
so strongly that they’ll bet their career on 
it. And if they will, I’ll bet 10 million dol-
lars on them. We don’t offer tenure, so 
if someone wants the security of tenure 
after 6 or 7 years, this is not the place 
for them.”
Changing the Game
A common complaint among research-
ers is that in order to be funded, they 
feel they must submit conservative 14 Cell 139, October 2, 2009 ©2009 Elseviergrants filled with so much preliminary 
data that their predictions aren’t quite 
predictions anymore. As Venter says, 
“The problem in [grant] study sec-
tions is the philosophy of proposals 
being reviewed as contracts instead of 
ideas.”
Since 1986, molecular biologist Keith 
Yamamoto of the University of California, 
San Francisco, has been a constructive 
critic of the NIH grant peer review sys-
tem and has served on various commit-
tees to fix it. He co-chaired the advisory 
committee to overhaul NIH grant peer 
review beginning in 2007, after former 
NIH director, Elias Zerhouni, stressed 
the need to improve the system and 
create space for scientists to take risks. 
Yamamoto’s committee made a series 
of recommendations including the TR01 
grants that are now being implemented. 
Last week, the NIH announced TR01 
grant awards to 42 applicants out of a 
pool of 700.
Yamamoto says that in the future he 
will push to extend that time limit and also 
to eliminate the list of topics currently in 
the grant description (e.g., new protein 
capture reagents, functional variations in 
mitochondria, and pharmacogenomics) 
that the NIH thinks are in particular need 
of high-risk/high-reward research.
This fiscal year (October 1, 2008–Sep-
tember 30, 2009), Congress will provide 
$35 million to the TR01 program—a sig-
nificant amount considering that if the 
program works, many projects should 
be expected to fail given their high-risk 
nature. However, it is a drop in the bucket 
compared to the $9.956 billion that was 
earmarked to fund regular R01 awards 
last year.
Yamamoto, now a TR01 study section 
co-chair, says, “The goal of the TR01s is 
to first of all recognize that peer review 
is intrinsically conservative. If we ask 
scientists to judge the scientific merit 
of an application, the tendency is that 
the grants that score highest will be 
those that represent the ideas of the 
day because the people who make the 
judgments are the ones who create the 
ideas of the day. There is a tendency 
to believe that ‘if you think like I think 
then I think you’re smart.’ This is a prob-
lem and now we are trying to address 
this intrinsic weakness in the system,” 
he says. The TR01 review process dif- Inc.fers in that scientific generalists first sift 
through the grants and chose 100 to 
be sent to appropriate specialists. The 
experts’ comments are then returned 
to the panel of generalists, who discuss 
each application’s overall transforma-
tive impact taking the specialists’ advice 
into account.
If the TR01 program is a success, 
one or two projects should eventually 
transform a field or create a new one. In 
order for that to happen, the NIH needs 
the best thinkers to submit their boldest 
ideas. “The word on the street is that the 
federal support system will never fund 
ideas that are far out,” Yamamoto says. 
“If we can’t establish our credibility to the 
people who think transformatively, the 
program won’t work. Many people feel 
like they’ve been tricked before, so this 
time around there will be a lot of pres-
sure on us to pick the right proposals.”
“With the TR01, the NIH created a 
program that would encourage bold and 
creative investigator-initiated research,” 
writes NIH Director Francis Collins in an 
email message. “As I have said before, 
I believe that the mainstay of NIH, both 
extramural and intramural, will be the 
creativity of individual investigators.”
Raising the Stakes
The NIH is not alone in setting aside 
funds for high-risk/high-reward research. 
Joanne Tornow, director of the Molecular 
and Cellular Biology division at the NSF 
says, “With the Recovery Act money 
there has been a little more free space 
for the program directors to reach out for 
projects that may be transformative.” This 
fiscal year, the NSF awarded more than 
twice as many EAGER (EArly concept 
Grants for Exploratory Research) awards 
in molecular and cellular biology than 
it did last year for EAGER’s precursor, 
the SGER awards, totaling $3.5 million. 
EAGER proposals are reviewed internally 
by NSF in order to avoid the conserva-
tive tendencies of review panels, and 
little preliminary data are required. They 
are awarded for 2 years for a maximum 
of $300,000 (regardless of duration), at 
which point researchers are expected 
to have sufficient data to obtain grant 
money from more mainstream sources. 
NSF’s small awards for exploratory stud-
ies have proven successful in the past. 
For example, Pamela Green and Blake 
Meyers at the University of Delaware 
changed how molecular biologists think 
about small noncoding RNAs with the 
results of their research funded by a 
2004 SGER award. They used the funds 
to develop high-throughput methods to 
analyze small noncoding RNAs in plants 
and discovered a much greater abun-
dance and variety of these RNAs than 
previously realized.
In March 2009, the European Com-
mission announced plans to strengthen 
its 20-year-old funding scheme called 
Future and Emerging Technologies 
(FET). This year, they scaled up their 
investment for FET projects to €100 mil-
lion from €90 million in 2008, and that 
figure is expected to rise to €170 million 
by 2013. FET grants typically offer €2–2.5 
million for projects lasting an average of 
3 years and support long-term, high-risk 
proposals backed by plausible research 
concepts that involve new technology. 
“We want to support research that will 
change scientific foundations,” says 
Prabhat Agarwal, a scientific officer in 
the scheme. “Innovation is a linear con-
cept, and we don’t want a pipeline. We 
want to create an intellectual ecosystem 
that will change scientific foundations in 
the long term.”A Recipe for Creativity
Nontraditional conferences designed to 
accelerate the pace of scientific dis-
covery have been cropping up around 
the US and, occasionally, they come 
with prizes. At the 5-day Sandpit meet-
ing held March 30–April 3 this year near 
Washington DC and sponsored by the 
NSF and the UK Engineering and Physi-
cal Science Research Council, scien-
tists from different backgrounds formed 
groups consisting of researchers from 
the UK and the US to discuss how to 
address problems in synthetic biology. 
At the end of the meeting, certain groups 
were invited to submit brief proposals 
based on their ideas. On September 1st, 
£3 million from the UK and $5.2 million 
from the US (roughly $10 million total) 
was divided up among five groups. One 
team of winning researchers proposes 
to develop synthetic integrons (mobile 
DNA elements that capture and carry 
genes via site-specific recombination, 
converting them to functional genes by 
expression of an internal promoter) in 
order to facilitate the evolution of new 
phenotypes.
In a similar vein, yearly conferences 
held since 2003 by the National Acad-
emies Keck Futures Initiative program Cell 1bring together scientists from different 
fields to discuss problems associated 
with a chosen theme. A 15-year, $40 mil-
lion dollar donation from the Keck Foun-
dation to spur interdisciplinary research 
allows the Academies to award $1 mil-
lion to winning projects each year. Last 
year, for example, under the “complex 
systems” theme, $50,000 went to a proj-
ect to find breath-based biomarkers for 
diagnosing early-stage lung cancer. And 
in 2006, under the “genomics and dis-
ease” theme, $75,000 went to research-
ers to optimize techniques for assessing 
the role of nitric oxide on white blood 
cells during inflammation and infection 
in human cell cultures. These awards 
are intended to help researchers acquire 
preliminary data so that they can apply 
for regular grants in the future.
With an increased emphasis on trans-
formative research, who knows what 
exciting scientific discoveries await us. 
Emphatically, Yamamoto says, “We 
should support research that is revo-
lutionary, that holds up an idea and 
says everything you thought about this 
process is wrong. We should support 
research that is destructive of a cur-
rent view, that says nope, think about it 
again.”
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